Basic Information
| LncRNA/CircRNA Name | lncRNA625 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | esophageal cancer |
| ICD-0-3 | C15 |
| Methods | qRT-PCR , Luciferase reporter assay , RIP , in vitro knockdown etc. |
| Sample | human esophageal cancer cell lines (KYSE150, KYSE510 and KYSE180 HEK293T cells) ,normal human ESCC cell line(SHEEC) |
| Expression Pattern | up-regulated |
| Function Description | We implicated lncRNA625 in the inhibition of STAT1 activity. LncRNA625 knockdown up-regulated STAT1-mediated transcription and resulted in an increase of STAT1-mediated expression of IFITM2.lncRNA625 upregulation inhibited STAT1 reporter activity.lncRNA625 inhibited STAT1 binding to the promoter of IFITM2 in both untreated cells and following interferon-gamma (IFN-?) stimulation. LncRNA625 interacted with the DNA-binding (DB) domain of STAT1 and promoted STAT1 interaction with T-cell protein tyrosine phosphatase TC45 to dephosphorylate pSTAT1. |
| Pubmed ID | 31605752 |
| Year | 2019 |
| Title | LncRNA625 Inhibits STAT1-mediated Transactivation Potential in Esophageal Cancer Cells |
External Links
| Links for lncRNA625 | GenBank HGNC NONCODE |
| Links for esophageal cancer | OMIM COSMIC |